Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.

Caplin, M E; Baudin, E; Ferolla, P; Filosso, P; Garcia-Yuste, M; Lim, E; Oberg, K; Pelosi, G; Perren, Aurel; Rossi, R E; Travis, W D (2015). Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Annals of oncology, 26(8), pp. 1604-1620. Oxford University Press 10.1093/annonc/mdv041

[img] Text
Ann Oncol-2015-Caplin-annonc_mdv041.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (366kB) | Request a copy
[img]
Preview
Text
mdv041.pdf - Other
Available under License Publisher holds Copyright.

Download (356kB) | Preview

BACKGROUND Pulmonary carcinoids (PCs) are rare tumors. As there is a paucity of randomized studies, this expert consensus document represents an initiative by the European Neuroendocrine Tumor Society to provide guidance on their management. PATIENTS AND METHODS Bibliographical searches were carried out in PubMed for the terms 'pulmonary neuroendocrine tumors', 'bronchial neuroendocrine tumors', 'bronchial carcinoid tumors', 'pulmonary carcinoid', 'pulmonary typical/atypical carcinoid', and 'pulmonary carcinoid and diagnosis/treatment/epidemiology/prognosis'. A systematic review of the relevant literature was carried out, followed by expert review. RESULTS PCs are well-differentiated neuroendocrine tumors and include low- and intermediate-grade malignant tumors, i.e. typical (TC) and atypical carcinoid (AC), respectively. Contrast CT scan is the diagnostic gold standard for PCs, but pathology examination is mandatory for their correct classification. Somatostatin receptor imaging may visualize nearly 80% of the primary tumors and is most sensitive for metastatic disease. Plasma chromogranin A can be increased in PCs. Surgery is the treatment of choice for PCs with the aim of removing the tumor and preserving as much lung tissue as possible. Resection of metastases should be considered whenever possible with curative intent. Somatostatin analogs are the first-line treatment of carcinoid syndrome and may be considered as first-line systemic antiproliferative treatment in unresectable PCs, particularly of low-grade TC and AC. Locoregional or radiotargeted therapies should be considered for metastatic disease. Systemic chemotherapy is used for progressive PCs, although cytotoxic regimens have demonstrated limited effects with etoposide and platinum combination the most commonly used, however, temozolomide has shown most clinical benefit. CONCLUSIONS PCs are complex tumors which require a multidisciplinary approach and long-term follow-up.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Perren, Aurel

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

0923-7534

Publisher:

Oxford University Press

Language:

English

Submitter:

Doris Haefelin

Date Deposited:

13 Jul 2015 10:37

Last Modified:

23 Oct 2019 17:53

Publisher DOI:

10.1093/annonc/mdv041

PubMed ID:

25646366

Uncontrolled Keywords:

atypical carcinoid; bronchial; carcinoid; neuroendocrine tumor; pulmonary; typical carcinoid

BORIS DOI:

10.7892/boris.70201

URI:

https://boris.unibe.ch/id/eprint/70201

Actions (login required)

Edit item Edit item
Provide Feedback